Clinical Research Directory
Browse clinical research sites, groups, and studies.
Bacteriophage Clinical Trial for Periprosthetic Joint Infection of Multidrug Resistant Pseudomonas Aeruginosa
Sponsor: Ottawa Hospital Research Institute
Summary
This is a single patient study (SPS) that aims to test the bacteriophage treatment as an experimental treatment on a patient suffering from chronic periprosthetic joint infection (PJI) of the right hip. This patients has been suffering from an infection in the right sided hip arthroplasty with a multidrug resistant (MDR) strain of Pseudomonas aeruginosa bacteria. All treatment options for this type of infection have been exhausted. If this patient remains without treatment then there is a high risk of mortality secondary to sepsis and the only remaining surgical option for this patient is a hind quarter amputation which will be a devastating surgery that will largely affect this patients quality of life. However, a large number of published case series have shown the positive impact of combining bacteriophage therapy with antibiotics to achieve a synergistic antibacterial effect and overcome possible resistance development to clear the infection. Therefore the investigators intend to try the bacteriophage therapy on this patients infected hip in the aim to control the infection and improve the patients quality of life.
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-06-04
Healthy Volunteers
Not specified
Conditions
Interventions
Combining bacteriophage therapy with antibiotics for a case with hip PJI
The treatment plan is to treat the patient with weekly intra-articular injections of a personalized phage therapy cocktail (QDP-PSA-011) for 3 consecutive weeks. This will be associated with antibiotics for 6 weeks.
Locations (1)
The Ottawa Hospital
Ottawa, Canada